GABA, Depression and Suicide

Advances in Biological Psychiatry

Volumn 30, Issue , 2015, Pages 37-50

  Pabba, Mohan ^a   Sibille, Etienne ^a,b,c  

^a CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^b Departments of Psychiatry   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84945130601     PISSN: 03787354     EISSN: 16622774     Source Type: Book Series    
DOI: 10.1159/000434736     Document Type: Article

References (101)

1. American Psychiatric Association: The Diagnostic and Statistical Manual of Mental Disorders: DSM-VTR, ed 5. Washington, APA, 2013.
2. WHO: International Classification of Mental and Behavioral Disorders, ed 10, rev. Geneva, WHO, 1992.
3. Friedman ES: Handbook of Depression, ed 2. London, Springer, 2014, pp 1-11.
4. Kessler RC, et al: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005; 62: 593-602.
5. Waraich P, et al: Prevalence and incidence studies of mood disorders: a systematic review of the literature. Can J Psychiatry 2004; 49: 124-138.
6. Bostwick JM, Pankratz VS: Affective disorders and suicide risk: a reexamination. Am J Psychiatry 2000; 157: 1925-1932.
7. Harris EC, Barraclough B: Suicide as an outcome for mental disorders. A meta-Analysis. Br J Psychiatry 1997; 170: 205-228.
8. WHO: The Global Burden of Disease -2004 update. Geneva, WHO, 2004.
9. Northoff G, Sibille E: Why are cortical GABA neurons relevant to internal focus in depression? A cross-level model linking cellular, biochemical and neural network findings. Mol Psychiatry 2014; 19: 966-977.
10. Beverly French, Seney ML, Sibille E: Altered GABA function in major depression; in Popoli M, Diamond D, Sanacora G (eds): Synaptic Stress and Pathogenesis of Neuropsychiatric Disorders. New York, Springer, 2014, pp 203-223.
11. Sibille E, French B: Biological substrates underpinning diagnosis of major depression. Int J Neuropsychopharmacol 2013; 16: 1893-1909.
12. Mann JJ: Neurobiology of suicidal behaviour. Nat Rev Neurosci 2003; 4: 819-828.
13. Turecki G: The molecular bases of the suicidal brain. Nat Rev Neurosci 2014; 15: 802-816.
14. Pandey GN, et al: Protein kinase C in the postmortem brain of teenage suicide victims. Neurosci Lett 1997; 228: 111-114.
15. Roy A: Hypothalamic-pituitary-Adrenal axis function and suicidal behavior in depression. Biol Psychiatry 1992; 32: 812-816.
16. Asberg M, et al: Serotonin depression -A biochemical subgroup within the affective disorders? Science 1976; 191: 478-480.
17. Stanley M, Virgilio J, Gershon S: Tritiated imipramine binding sites are decreased in the frontal cortex of suicides. Science 1982; 216: 1337-1339.
18. Stanley M, Mann JJ: Increased serotonin-2 binding sites in frontal cortex of suicide victims. Lancet 1983; 1: 214-216.
19. Underwood MD, et al: Neuron density and serotonin receptor binding in prefrontal cortex in suicide. Int J Neuropsychopharmacol 2012; 15: 435-447.
20. Parsey RV, et al: Lower serotonin transporter binding potential in the human brain during major depressive episodes. Am J Psychiatry 2006; 163: 52-58.
21. Arango V, Underwood MD, Mann JJ: Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 2002; 136: 443-453.
22. Mann JJ, Brent DA, Arango V: The neurobiology and genetics of suicide and attempted suicide: a focus on the serotonergic system. Neuropsychopharmacology 2001; 24: 467-477.
23. Korpi ER, Kleinman JE, Wyatt RJ: GABA concentrations in forebrain areas of suicide victims. Biol Psychiatry 1988; 23: 109-114.
24. Berrettini WH, et al: Cerebrospinal fluid studies of bipolar patients with and without a history of suicide attempts. Ann NY Acad Sci 1986; 487: 197-201.
25. Roy A: Neuropeptides in relation to suicidal behavior in depression. Neuropsychobiology 1993; 28: 184-186.
26. Sundman I, et al: GABA uptake sites in frontal cortex from suicide victims and in aging. Neuropsychobiology 1997; 35: 11-15.
27. Cross JA, et al: Brain GABA B binding sites in depressed suicide victims. Psychiatry Res 1988; 26: 119-129.
28. Arranz B, et al: Gamma-Aminobutyric acid-B (GABA B ) binding sites in postmortem suicide brains. Neuropsychobiology 1992; 26: 33-36.
29. Gonzalez-Maeso J, et al: Neurotransmitter receptormediated activation of G-proteins in brains of suicide victims with mood disorders: selective supersensitivity of α 2A -Adrenoceptors. Mol Psychiatry 2002; 7: 755-767.
30. Sibille E, et al: Gene expression profiling of depression and suicide in human prefrontal cortex. Neuropsychopharmacology 2004; 29: 351-361.
31. Sequeira A, et al: Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 2009; 4: e6585.
32. Choudary PV, et al: Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci U S A 2005; 102: 15653-15658.
33. Merali Z, et al: Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA A receptor subunits in frontal cortical brain region. J Neurosci 2004; 24: 1478-1485.
34. Poulter MO, et al: Altered organization of GABA A receptor mRNA expression in the depressed suicide brain. Front Mol Neurosci 2010; 3: 3.
35. Poulter MO, et al: GABA A receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol Psychiatry 2008; 64: 645-652.
36. Klempan TA, et al: Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry 2009; 14: 175-189.
37. Zhurov V, et al: Molecular pathway reconstruction and analysis of disturbed gene expression in depressed individuals who died by suicide. PLoS One 2012; 7:e47581.
38. Bernstein HG, et al: Disruption of glutamate-glutamine-GABA cycle significantly impacts on suicidal behaviour: survey of the literature and own findings on glutamine synthetase. CNS Neurol Disord Drug Targets 2013; 12: 900-913.
39. Cheetham SC, et al: Brain GABAA/benzodiazepine binding sites and glutamic acid decarboxylase activity in depressed suicide victims. Brain Res 1988; 460: 114-123.
40. Sequeira A, et al: Patterns of gene expression in the limbic system of suicides with and without major depression. Mol Psychiatry 2007; 12: 640-655.
41. Lee R, Petty F, Coccaro EF: Cerebrospinal fluid GABA concentration: relationship with impulsivity and history of suicidal behavior, but not aggression, in human subjects. J Psychiatr Res 2009; 43: 353-359.
42. Rajkowska G, et al: GABAergic neurons immunoreactive for calcium binding proteins are reduced in the prefrontal cortex in major depression. Neuropsychopharmacology 2007; 32: 471-482.
43. Beasley CL, et al: Selective deficits in prefrontal cortical GABAergic neurons in schizophrenia defined by the presence of calcium-binding proteins. Biol Psychiatry 2002; 52: 708-715.
44. Cotter D, et al: The density and spatial distribution of GABAergic neurons, labelled using calcium binding proteins, in the anterior cingulate cortex in major depressive disorder, bipolar disorder, and schizophrenia. Biol Psychiatry 2002; 51: 377-386.
45. Maciag D, et al: Reduced density of calbindin immunoreactive GABAergic neurons in the occipital cortex in major depression: relevance to neuroimaging studies. Biol Psychiatry 2010; 67: 465-470.
46. Sibille E, et al: GABA-related transcripts in the dorsolateral prefrontal cortex in mood disorders. Int J Neuropsychopharmacol 2011; 14: 721-734.
47. Tripp A, et al: Reduced somatostatin in subgenual anterior cingulate cortex in major depression. Neurobiol Dis 2011; 42: 116-124.
48. Tripp A, et al: Brain-derived neurotrophic factor signaling and subgenual anterior cingulate cortex dysfunction in major depressive disorder. Am J Psychiatry 2012; 169: 1194-1202.
49. Guilloux JP, et al: Molecular evidence for BDNF-And GABA-related dysfunctions in the amygdala of female subjects with major depression. Mol Psychiatry 2012; 17: 1130-1142.
50. Martel G, et al: Somatostatinergic systems: an update on brain functions in normal and pathological aging. Front Endocrinol (Lausanne) 2012; 3: 154.
51. Karolewicz B, et al: Reduced level of glutamic acid decarboxylase-67 kDa in the prefrontal cortex in major depression. Int J Neuropsychopharmacol 2010; 13: 411-420.
52. Hasler G, et al: Reduced prefrontal glutamate/glutamine and gamma-Aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. Arch Gen Psychiatry 2007; 64: 193-200.
53. Levinson AJ, et al: Evidence of cortical inhibitory deficits in major depressive disorder. Biol Psychiatry 2010; 67: 458-464.
54. Gabbay V, et al: Anterior cingulate cortex gammaaminobutyric acid in depressed adolescents: relationship to anhedonia. Arch Gen Psychiatry 2012; 69: 139-149.
55. Hasler G, Northoff G: Discovering imaging endophenotypes for major depression. Mol Psychiatry 2011; 16: 604-619.
56. Sanacora G, et al: Increased occipital cortex GABA concentrations in depressed patients after therapy with selective serotonin reuptake inhibitors. Am J Psychiatry 2002; 159: 663-665.
57. Sanacora G, et al: Increased cortical GABA concentrations in depressed patients receiving ECT. Am J Psychiatry 2003; 160: 577-579.
58. Northoff G, et al: GABA concentrations in the human anterior cingulate cortex predict negative BOLD responses in fMRI. Nat Neurosci 2007; 10: 1515-1517.
59. Brambilla P, et al: GABAergic dysfunction in mood disorders. Mol Psychiatry 2003; 8: 721-737, 715.
60. Luscher B, Shen Q, Sahir N: The GABAergic deficit hypothesis of major depressive disorder. Mol Psychiatry 2011; 16: 383-406.
61. Emrich HM, et al: Effect of sodium valproate on mania. The GABA-hypothesis of affective disorders. Arch Psychiatr Nervenkr 1980; 229: 1-16.
62. Gold BI, et al: GABA levels in CSF of patients with psychiatric disorders. Am J Psychiatry 1980; 137: 362-364.
63. Petty F, Schlesser MA: Plasma GABA in affective illness. A preliminary investigation. J Affect Disord 1981; 3: 339-343.
64. Petty F, Sherman AD: Plasma GABA levels in psychiatric illness. J Affect Disord 1984; 6: 131-138.
65. Gerner RH, Hare TA: CSF GABA in normal subjects and patients with depression, schizophrenia, mania, and anorexia nervosa. Am J Psychiatry 1981; 138: 1098-1101.
66. Earnheart JC, et al: GABAergic control of adult hippocampal neurogenesis in relation to behavior indicative of trait anxiety and depression states. J Neurosci 2007; 27: 3845-3854.
67. Mayberg HS, et al: Deep brain stimulation for treatment-resistant depression. Neuron 2005; 45: 651-660.
68. Morris HM, Hashimoto T, Lewis DA: Alterations in somatostatin mRNA expression in the dorsolateral prefrontal cortex of subjects with schizophrenia or schizoaffective disorder. Cereb Cortex 2008; 18: 1575-1587.
69. Konradi C, et al: Hippocampal interneurons in bipolar disorder. Arch Gen Psychiatry 2011; 68: 340-350.
70. Konradi C, et al: Molecular evidence for mitochondrial dysfunction in bipolar disorder. Arch Gen Psychiatry 2004; 61: 300-308.
71. Timmers HJ, et al: Somatostatin 1-12 immunoreactivity is decreased in the hypothalamic lateral tuberal nucleus of Huntingtons disease patients. Brain Res 1996; 728: 141-148.
72. Davies P, Katzman R, Terry RD: Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementia. Nature 1980; 288: 279-280.
73. Epelbaum J, et al: Somatostatin, Alzheimers disease and cognition: an old story coming of age? Prog Neurobiol 2009; 89: 153-161.
74. Epelbaum J, et al: Somatostatin receptors in brain and pituitary. Horm Res 1989; 31: 45-50.
75. Lin LC, Sibille E: Reduced brain somatostatin in mood disorders: a common pathophysiological substrate and drug target? Front Pharmacol 2013; 4: 110.
76. Lin LC, Sibille E: Somatostatin, neuronal vulnerability and behavioral emotionality. Mol Psychiatry 2015; 20: 377-387.
77. Dwivedi Y: Brain-derived neurotrophic factor in suicide pathophysiology; in Dwivedi Y (ed): The Neurobiological Basis of Suicide. Boca Raton, CRC Press, 2012.
78. Pandey GN, et al: Brain-derived neurotrophic factor and tyrosine kinase B receptor signalling in postmortem brain of teenage suicide victims. Int J Neuropsychopharmacol 2008; 11: 1047-1061.
79. Dwivedi Y, et al: Altered gene expression of brainderived neurotrophic factor and receptor tyrosine kinase B in postmortem brain of suicide subjects. Arch Gen Psychiatry 2003; 60: 804-815.
80. Keller S, et al: Increased BDNF promoter methylation in the Wernicke area of suicide subjects. Arch Gen Psychiatry 2010; 67: 258-267.
81. Perroud N, et al: Interaction between BDNF Val-66Met and childhood trauma on adults violent suicide attempt. Genes Brain Behav 2008; 7: 314-322.
82. Pregelj P, et al: The association between brain-derived neurotrophic factor polymorphism (BDNF Val66Met) and suicide. J Affect Disord 2011; 128: 287-290.
83. Deltheil T, et al: Synergistic neurochemical and behavioural effects of acute intrahippocampal injection of brain-derived neurotrophic factor and antidepressants in adult mice. Int J Neuropsychopharmacol 2009; 12: 905-915.
84. Shirayama Y, et al: Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002; 22: 3251-3261.
85. Karege F, et al: Neurotrophin levels in postmortem brains of suicide victims and the effects of antemortem diagnosis and psychotropic drugs. Brain Res Mol Brain Res 2005; 136: 29-37.
86. Block SG, Nemeroff CB: Emerging antidepressants to treat major depressive disorder. Asian J Psychiatr 2014; 12: 7-16.
87. Bersani FS, et al: Deep transcranial magnetic stimulation as a treatment for psychiatric disorders: a comprehensive review. Eur Psychiatry 2013; 28: 30-39.
88. Sher L, Mindes J, Novakovic V: Transcranial magnetic stimulation and the treatment of suicidality. Expert Rev Neurother 2010; 10: 1781-1784.
89. Desmyter S, et al: The acute effects of accelerated repetitive transcranial magnetic stimulation on suicide risk in unipolar depression: preliminary results. Psychiatr Danub 2014; 26(suppl 1):48-52.
90. Rapinesi C, et al: Alcohol and suicidality: could deep transcranial magnetic stimulation (dTMS) be a possible treatment? Psychiatr Danub 2014; 26: 281-284.
91. Hadley D, et al: Safety, tolerability, and effectiveness of high doses of adjunctive daily left prefrontal repetitive transcranial magnetic stimulation for treatment-resistant depression in a clinical setting. J ECT 2011; 27: 18-25.
92. George MS, et al: A two-site pilot randomized 3 day trial of high dose left prefrontal repetitive transcranial magnetic stimulation (rTMS) for suicidal inpatients. Brain Stimul 2014; 7: 421-431.
93. Padberg F, George MS: Repetitive transcranial magnetic stimulation of the prefrontal cortex in depression. Exp Neurol 2009; 219: 2-13.
94. OReardon JP, et al: Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry 2007; 62: 1208-1216.
95. Kujirai T, et al: Corticocortical inhibition in human motor cortex. J Physiol 1993; 471: 501-519.
96. Cantello R, et al: Magnetic brain stimulation: the silent period after the motor evoked potential. Neurology 1992; 42: 1951-1959.
97. Siebner HR, et al: Continuous intrathecal baclofen infusions induced a marked increase of the transcranially evoked silent period in a patient with generalized dystonia. Muscle Nerve 1998; 21: 1209-1212.
98. Ziemann U, et al: Effects of antiepileptic drugs on motor cortex excitability in humans: a transcranial magnetic stimulation study. Ann Neurol 1996; 40: 367-378.
99. Thompson SM, Gahwiler BH: Effects of the GABA uptake inhibitor tiagabine on inhibitory synaptic potentials in rat hippocampal slice cultures. J Neurophysiol 1992; 67: 1698-1701.
100. de Jesus DR, et al: Determining optimal rTMS parameters through changes in cortical inhibition. Clin Neurophysiol 2014; 125: 755-762.
101. Daskalakis ZJ, et al: The effects of repetitive transcranial magnetic stimulation on cortical inhibition in healthy human subjects. Exp Brain Res 2006; 174: 403-412.